Evidence map›Paper›PMID 28787336›Full record

ArticlePancreas2017

Anticancer Effects of Baicalein in Pancreatic Neuroendocrine Tumors In Vitro and In Vivo.

Ye Tian, Liang Zhen, Jian'an Bai, Yumei Mei, Zheng Li, Aihua Lin, Xueliang Li

Open access · hybridAbstract read
In one paragraph

Article in Pancreas, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ye TianFrom the *Department of Gastroenterology, Nanjing Medical University; †Department of Gastroenterology, Affiliated Run Run Shaw Hospital of Nanjing Medical University; and ‡Department of Gastroenterology, Jiangsu Second Hospital of Traditional Chinese Medicine, Nanjing; and §Department of Intensive Care Unit, Affiliated SuQian Hospital of Drum Tower Hospital, SuQian, China.
Liang Zhen
Jian'an Bai
Yumei Mei
Zheng Li
Aihua Lin
Xueliang Li
Nanjing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesBaicalein is a Chinese traditional medicine that inhibits tumor migration and growth. Pancreatic neuroendocrine tumors (pNETs) have a high incidence in China, but there are still no effective treatments. The aim of our study was to investigate whether baicalein could inhibit pNETs.

methodsIn vitro, we used BON1-a cell line of pNETs-to analyze the apoptosis and migration and invasion after baicalein treatment via flow cytometry and Western blot. In vivo, we used a xenograft tumors model to evaluate the size of tumors after baicalein treatment. Western blot was used to analyze the expression of apoptosis and migration-related protein.

resultsIn vitro, the Cell Counting Kit 8 assay showed that baicalein decreased BON1 viability, and flow cytometry demonstrated that baicalein induced BON1 apoptosis and protein changes. In addition, baicalein inhibited BON1 migration and invasion as shown via a Transwell assay. In vivo, baicalein inhibited tumor growth and migration and also increased apoptosis-related protein expression.

conclusionsBaicalein could increase caspase-3 and Bax expression and decrease survivin and Bcl-2 to induce apoptosis. It inhibits migration and invasion by decreasing expression of vascular endothelial growth factor and matrix metalloproteinases 2 and 9.

Indexed as

Xenograft Model Antitumor AssaysAnimalsAntineoplastic AgentsApoptosisApoptosis Regulatory ProteinsCaspase 3Cell Line, TumorCell MovementFemaleFlavanonesHumansMatrix Metalloproteinase 2Matrix Metalloproteinase 9Mice, NudeNeoplasm InvasivenessNeuroendocrine TumorsAntineoplastic AgentsApoptosis Regulatory ProteinsbaicaleinCaspase 3FlavanonesMatrix Metalloproteinase 2Matrix Metalloproteinase 9

Identifiers

PMID28787336
PMCPMC5555971
OpenAlexW2743645564

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.